We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Randox and Bosch Partner to Launch Molecular Diagnostics Platform

By LabMedica International staff writers
Posted on 01 Mar 2018
Print article
Image: The Vivalytic all-in-one fully automated solution for molecular diagnostics (Photo courtesy of Randox Laboratories and Bosch Healthcare Solutions).
Image: The Vivalytic all-in-one fully automated solution for molecular diagnostics (Photo courtesy of Randox Laboratories and Bosch Healthcare Solutions).
Global healthcare diagnostics manufacturer Randox Laboratories (Crumlin, Northern Ireland, UK) has partnered with Bosch Healthcare Solutions GmbH (Waiblingen, Germany) to launch Vivalytic, an all-in-one fully automated solution for molecular diagnostics.

Randox develops, manufactures and markets diagnostic reagents and equipment for laboratory medicine. Its range of products includes Biochip Array Technology, clinical chemistry analyzers and reagents, quality control materials and schemes and an extensive life science portfolio. The company’s products and services are used in hospitals, clinical, research and molecular laboratories, food testing, forensic toxicology, life sciences, and veterinary laboratories.

Bosch Healthcare Solutions GmbH, a wholly owned subsidiary of Robert Bosch GmbH, develops products and services to improve people’s health and quality of life. The subsidiary’s solutions draw on the Bosch Group’s core competencies: sensors to collect data, software to evaluate that data, and services based on this data analysis.

Vivalytic combines the broadest range of test options and uses Randox-patented Biochip Array Technology, making it the easiest to use and most comprehensive multiplex PCR platform in the market. The device also supports single-plex and low-plex testing, simplifying the processes for otherwise complex laboratory test procedures. Depending upon the test application, Vivalytic delivers results from 30 minutes.

The first tests available on the Vivalytic are Randox’s panels for respiratory and sexually transmitted infections. The Respiratory Multiplex Array simultaneously detects 22 viral and bacterial pathogens, including Bordetella parapertussis, without the need for secondary or confirmatory testing to inform clinical treatment decisions. The STI array enables the detection of 10 viral, bacterial and protozoan STIs from a single urine or urogenital swab sample.

“This is transformational for patients and doctors; never before has there been this level of accessibility to such a wealth of molecular tests. Randox molecular assays continue to evolve, keeping precise diagnostics for targeted patient therapy at the centre. With Vivalytic, there’s no limit to the testing portfolio that can be made available on its universal platform, and importantly it delivers results quickly and accurately,” said Dr Peter FitzGerald, MD of Randox Laboratories.

“This is an ideal partnership for Randox, combining our expertise in molecular laboratory diagnostics with Bosch’s cutting-edge engineering. With antibiotic resistance one of the most pressing public health issues faced across the world today, we’re delighted that the first tests available on Vivalytic are our industry-leading multiplex panels for respiratory and sexually transmitted infections. This Randox-Bosch partnership enables quick, accurate diagnosis, improved patient care and the effective stewardship of critical medicines.”

“We are enthusiastic about having gained Randox as the first partner on our platform with two initial panels available from the start. It´s the beginning of jointly expanding the Vivalytic test portfolio for our clients,” said Marc Meier, General Manager of Bosch Healthcare Solutions. “In this partnership the core competencies of Bosch in automation, miniaturization, and networking are complemented by Randox’s expertise in developing and commercializing innovative diagnostic solutions.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.